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Abstract
Background
Continuous veno-venous hemodialysis with high cut-off membranes (HCO-CVVHD)
removes inflammatory mediators involved in organ dysfunction during sepsis. The aim of
the present study was to assess the variations in SOFA score and identify early predictors
of short-term mortality in a cohort of patients with septic shock, treated with HCO-CVVHD
for acute kidney injury (AKI).
Methods
An observational prospective multicenter cohort study was conducted in four mixed medi-
cal-surgical ICUs. Thirty-eight patients with septic shock and AKI (KDIGO stage1) treated
with HCO-CVVHD have been included in this study. Patients were divided into Survivors
and non-Survivors according to mortality observed at 72nd hr of treatment. The variation of
SOFA scores and clinical/biochemical parameters were described over time for the entire
population and specifically for Survivors and non-Survivors. Similarly, circulating inflamma-
tory mediators (as IL-6, TNF-a and IL-10) were described over time. A logistic regression
analysis was used to identify the baseline clinical and biochemical parameters associated
with 72 hrs-ICU mortality.
Results
Overall, the mean SOFA score was 12±3 at baseline, 10.9±3 at 6hrs, 9.8±3 at 12hrs, 8.9
±3.3 at 24 hrs, and 8±3.5 at 48 hrs after HCO-CVVHD initiation; and 6.5±2.7 at 24 hrs and
6.6±3 at 48 hrs after HCO-CVVHD discontinuation. In the multivariate regression analysis,
baseline serum lactate levels and AKI stage independently correlated with short-term mor-
tality during HCO-CVVHD. A significant reduction was observed in circulating levels of
TNFα and IL-6 among Survivors.
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Conclusions
SOFA score significantly decreased early after initiation of HCO-CVVHD in patients with
septic AKI. Baseline lactate levels and the AKI stage resulted to be associated to 72 hrs-
ICU-mortality.
Introduction
Severe sepsis and septic shock are common causes of death among patients admitted to inten-
sive care units (ICUs) [1,2]. Acute kidney injury (AKI) is an independent risk factor for death
in these patients [3]. Persistent systemic inflammation, immunoparalysis and secondary infec-
tions are thought to play key roles in sepsis-related organ dysfunction [4]; indeed, an imbal-
ance between pro- (e.g. IL-1 and 6, TNFα) and anti-inflammatory (e.g. IL-4 and 10) cytokines
may be associated with a worse clinical outcome [5]. Unselective removal of inflammatory and
anti-inflammatory mediators by means of blood purification therapies may positively impact
organ dysfunction in septic patients, particularly regarding hemodynamic and respiratory
functions [6]. As such, continuous veno-venous hemodialysis with high cut-off membrane
(HCO-CVVHD) has been used as an adjuvant therapy in septic patients with AKI [7]. The
higher-than-standard pore size (i.e. >0.01μm) allows HCO to remove large molecules such as
inflammatory mediators [6]. The aim of this observational study was to describe the variations
in Sequential Organ Failure Assessment (SOFA) scores, and to identify baseline clinical and
biochemical parameters statistically associated with early mortality in a cohort of patients with
septic shock, treated with HCO-CVVHD for AKI.
Material and methods
This was an observational prospective multicenter study performed in four mixed general
ICUs. The regional Ethical Board (“Comitato Etico di Area Vasta Centro, Regione Toscana”)
reviewed and approved the protocol for all participating centers (n˚ 2013/0024940). The con-
sent for analysis and publication of clinical data have been written obtained by the patients, if
conscious. If the patient was not able to sign consent forms at the study enrollment, permission
for analysis and publication of clinical data was obtained before the patient’s ICU discharge
(for survived patients) or it was waived (for dead patients) in accordance with local ethics
committee. Consent forms are stored in the ICU of the principal investigator (Prof. A. R De
Gaudio).
All patients with septic shock (defined according to the Surviving Sepsis Campaign guide-
lines [8]) and AKI (defined as a KDIGO stage1 [9]) undergoing HCO-CVVHD were consid-
ered for inclusion. Inclusion and exclusion criteria are described in Fig 1. HCO-CVVHD was
performed using a Prismaflex machine (Gambro Lundia AB–Lund, Sweeden) and SepteX
membranes (a polyarylethersulfone high cut-off membrane with a 1.1m2 surface area; Gambro
Lundia AB–Lund, Sweeden) in all patients. Treatment parameters prescribed and actually
delivered during HCO-CVVHD have been derived from memory cards within Prismaflex
machines used. Clinical and biochemical observations have been limited at the first 72 hrs of
treatment with HCO-CVVHD, i.e. the maximum time of treatment achievable with a single
extracorporeal circuit according to the filter manufacturer. According to local routine clinical
practice, HCO-CVVHD discontinuation has been decided according to recovery of clinical
stability (mostly in terms of hemodynamic status) and renal function. In particular, at the end
of the HCO filter life-span, if patient was clinically improved and able to maintain an adequate
Organ dysfunction during HCO-CVVHD
PLOS ONE | DOI:10.1371/journal.pone.0172039 February 16, 2017 2 / 13
coordination, statistical analysis and recruitment of
investigators for this study. The funders had no
role in study design, data collection and analysis,
decision to publish, or preparation of the
manuscript.
Competing interests: We have the following
interests: Baxter has provided a grant to the
Department of Health Science of the University of
Florence for the cytokine analysis. GV received
from Baxter support for travel expenses, hotel
accommodations, and registration to meetings. CC
received honoraria for lectures by Orion Pharma; a
grant for consultancy by Astellas; support for
meetings (travel, hotel accommodations and/or
registration) by BBraun, Astellas, MSD, Pfizer, Pall
International, Baxter, Orion Pharma. ARDG
received research grants from MSD Italia, Baxter,
Pall international. SR received from Baxter, Orion
Pharma, and Vygon honoraria for lectures, from
ICU Medical, MSD and Medtronic grants for
consultancy, from Baxter, BBraun, Pall
International, and Vygon support for travel
expenses, hotel accommodations, and registration
to meetings. There are no patents, products in
development or marketed products to declare. This
does not alter our adherence to all the PLOS ONE
policies on sharing data and materials.
fluid balance/urinary flow/solute control (spontaneously or with diuretic administration), she
or he was considered adequately weaned from HCO-CVVHD. On the other hand, if clinical
stability was not associated with recovery of good renal function at the end of HCO life-span,
HCO-CVVHD was substituted with another CRRT modality performed with a high-flux
membrane (usually CVVHDF).
For sample size evaluation, the mean SOFA score in patients with AKI and sepsis, at base-
line and during the following four days, was derived from the literature [10]. Assuming a
mean mortality rate of 30% during the first 48 hrs of treatment, a sample size of 38 patients
was needed to observe a reduction in SOFA score equal to 2.5 at 48 hrs after HCO-CVVHD
initiation through a t-Student test for paired data with a power of 90% and a type I error rate
of 2.5%. The SOFA score reduction equal to 2.5 has been chosen considering this as the mini-
mal SOFA score variation with a clinical relevance.
Patients have been divided in “Survivors” and “non-Survivors” groups according to the occur-
rence of death during the 72 hrs of HCO-CVVHD. SOFA score, Acute Physiology and Chronic
Health Evaluation (APACHE) II, clinical and biochemical data were recorded at baseline, then at
6, 12, 24, and 48 hrs after HCO-CVVHD [11] initiation; and at 24 and 48 hrs after HCO-CVVHD
discontinuation. If another HCO-CVVHD treatment was required after these first 72 hrs, the lat-
ter time points were calculated from the discontinuation of the last HCO filter utilized. All param-
eters were described both for Survivors and non-Survivors groups. In addition, the circulating
levels of inflammatory mediators (IL-6, TNF-a and IL-10) were measured at baseline, then at 24
and 48 hrs after HCO-CVVHD initiation, and at 24 hrs after HCO-CVVHD discontinuation.
The Shapiro-Wilk test was used to test the data for normality. Continuous variables were
presented as mean ± standard deviation (SD) or median [I-III interquartile range] where
appropriate. The variations of these parameters over time with respect to the baseline were
evaluated using t-Student test for paired data or Wilcoxon signed-rank test, according to
data distribution. Similarly, the differences between Survivors and not- Survivors were tested
using t-Student test for un-paired data or Mann-Whitney Wilcoxon. Categorical variables
were analyzed using the chi-square test and given as a percentage. For each time point, a mean
Fig 1. Inclusion and exclusion criteria.
doi:10.1371/journal.pone.0172039.g001
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difference (SD) was expressed to evaluate the SOFA score trend in the observed population
with respect to the baseline value. Finally, the differences in baseline characteristics between
groups were analyzed through univariate and multivariate regression analysis in order to iden-
tify the baseline parameters associated with survival at 72 hrs of treatment. All variables with a
p value less than 0.3 at the univariate analysis have been considered for the multivariable analy-
sis. Statistical results were expressed as p value, Odds Ratio (OR) and 95% confidence interval
(95%CI). For continuous variables statistically associated with survival at 72 hrs of treatment
at multivariate analysis, a ROC analysis was performed in order to analyze its accuracy in pre-
dicting outcome and to identify a cut-off value applicable in clinical practice.
Data were analyzed using STATA 9.1 software (STATA corp, 490, Lakeway Drive College
Station, 77845, Texas, US).
Results
The study included 38 patients (S1 Table) enrolled from March 2013 to September 2014. Of
these, 17 (44.7%) were medical and 21 (55.2%) were surgical. Table 1 summarizes baseline
patients’ clinical characteristics for the entire population and specifically for Survivors (N = 30)
and non-Survivors (N = 8). Prescribed and delivered treatment parameters for both groups, cal-
culated according to standard nomenclature [12,13], are described in Table 2. Excluding a tran-
sient hypotension at the HCO-CVVHD initiation that occurred in 5 patients, no others adverse
events have been reported during treatments. All hypotensive episodes have been mostly attrib-
uted to the blood filling into the extracorporeal circuit; they did not require further increase of
vasoactive drugs and spontaneously recovered. Exogenous replacement for albumin or coagula-
tion factors were necessary for none of the observed patients during treatments.
At the HCO-CVVHD initiation (baseline), the mean SOFA score was 12.03±3.02. During
treatment, the mean±SD values of SOFA score were 10.97±3 at 6 hrs (N = 38; p<0.001; mean
difference 1.05±1.45, 95%CI[0.58–1.53]), 9.82±3.03 at 12 hrs (N = 38; p<0.001; mean differ-
ence 2.21±1.99, 95%CI[1.56–2.86]), 8.91±3.34 at 24 hrs (N = 37; p<0.001; mean difference
3.03±2.72, 95%CI[2.12–3.93]), and 8±3.48 at 48 hrs after HCO-CVVHD initiation (N = 34;
p<0.001; mean difference 4.06±3.48, 95%CI[2.84–5.27]). After HCO-CVVHD discontinua-
tion, SOFA scores were 6.5±2.73 at 24 hrs (N = 30; p<0.001; mean difference 5.42±3.78, 95%
CI [3.96–6.90]) and 6.57±3.04 at 48 hrs (N = 30; p<0.001; mean difference 5.36±3.99, 95%CI
[3.80–6.90]). Fig 2 shows the variation of SOFA score over time for the entire population and
specifically for Survivors and non-Survivors groups. Clinical parameters observed for Survi-
vors and non-Survivors at each time point are presented in Table 3. TNFα and IL-6 signifi-
cantly decreased during the treatment, particularly for Survivors (p<0.05; see Table 3 and Fig
3). At multivariate logistic regression analysis the baseline serum lactate (p = 0.03, OR 1.45,
95%CI [1.01–2.06]) and initial KDIGO stage (p = 0.04, OR 7.79, 95%CI[0.93–65.4]) were in-
dependently associated to 72 hrs-ICU mortality. A ROC analysis for baseline lactate levels
has shown a ROC-AUC equal to 0.79 (95%CI, 0.57–1.00). Sensitivity and specificity related
to the different baseline lactate levels were calculated. With a sensitivity equals to 75% and a
specificity equals to 90%, a baseline lactate level of 5.2 mmol/l was identified as the cut-off
value that best distinguishes between patients who survived and those who died after 72 hrs
of HCO-CVVHD. Every patient not-survived during this observational study dead during
HCO-CVVHD. The cumulative hospital mortality rate for the entire cohort was 39.5%.
Discussion
It is well known that an adequate source control and an effective antibiotic treatment are the
only etiological therapies able to improve patient survival [8,14,15]. However, in selected cases,
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extracorporeal blood purification therapies (e.g. HCO-CVVHD) may positively affect clinical
outcome through multiple effects, including the reduction in inflammatory burden and restor-
ing immunocompetence [16].
Table 1. Baseline characteristics of the overall population and for the separate subgroups of Survivors and not- Survivors.
Variables Tot Survivors (N = 30) non-Survivors (N = 8) p OR 95%CI
Male gender 71.1% 73.3% 62.5% 0.55 0.60 0.11–3.14
Age (years) 74.5 [64–79] 75 [64–80] 72 [68.5–77] 0.76 1.01 0.94–1.09
Microorganisms
Klebsiella spp. 21.1% 20% 25% 0.43 2.99 0.20–44.73
E. coli 21.1% 20% 25% 0.36 4.32 0.18–97.53
Ps. aeruginosa 21.1% 20% 25% 0.37 3.80 0.21–69.85
St. aureus 21.1% 20% 25% 0.37 3.22 0.25–41.39
Str. pneumoniae 10.5% 10% 12.5% 0.45 3.22 0.16–68.19
Candida spp. 21.1% 20% 25% 0.91 1.14 0.14–9.53
Aspergillum spp. 10.5% 10% 12.5% 0.97 1.06 0.05–23.83
Other 18.4% 20% 12.5% 0.84 0.74 0.01–0.90
Source of infection
Pneumonia 31.6% 30% 37.5% 0.69 1.4 0.27–7.15
Peritonitis 23.7% 26.7% 12.5% 0.42 0.39 0.04–3.71
Urinary tract 10.5% 6.7% 25% 0.16 4.67 0.54–40.03
Blood stream 18.4% 16.7% 25% 0.59 1.67 0.26–10.77
Soft tissue 15.8% 16.7% 12.5% 0.78 0.71 0.07–7.16
APACHE II 37.55±3.55 37.6±3.06 38±2.92 0.89 0.99 0.89–1.11
SOFA 12.02±3.01 12.10±2.99 11.75±3.33 0.77 0.96 0.74–1.25
KDIGO 0.05 8.03 0.99–64.8
Stage 1 15.8% 20% 0%
Stage 2 34.2% 40% 12.5%
Stage 3 50% 40% 87.5%
Norepinephrine (mcg/kg/min) 0.20 [0.15–0.30] 0.23 [0.15–0.30] 0.18 [0.08–0.33] 0.77 0.38 0.0–292.57
SAP (mmHg) 103±27 105±26 95±27 0.34 0.98 0.95–1.01
MAP (mmHg) 65±15 67±15 60±14 0.24 0.96 0.91–1.03
Heart rate (bpm) 83 [80–100] 83 [80–99] 88 [80–106] 0.37 1.02 0.98–1.06
CVP (mmHg) 12±4 11±4 13±5 0.32 1.11 0.91–1.36
RR (breath/min) 18±6 18±6 18±5 0.89 0.99 0.86–1.14
PaO2/FiO2 230±126 227±117 240±126 0.79 1.00 0.99–1.00
PEEP (cmH2O) 6 [5–8] 6 [4–8] 7 [6–8] 0.36 1.15 0.86–1.53
Arterial HCO3- (mmol/L) 22.3±3.9 22.9±3.8 19.8±3.4 0.05 0.75 0.56–0.99
Lactate (mmol/L) 2.5 [1.5–4.8] 2.4 [1.4–3.3] 6.3 [3.7–14.3] 0.01 1.35 1.06–1.71
ScvO2 (%) 58±15 60±15 55±14 0.44 0.98 0.92–1.04
WBC (109/L) 17.89±11.72 18.20±12.17 16.73±10.53 0.75 0.99 0.92–1.06
Plt (109/L) 97 [67–226] 100 [68–226] 83[33.5–206.5] 0.78 1.00 0.99–1.00
AT (%) 60±21 62±21 54±23 0.38 0.98 0.94–1.02
PCT (ng/ml) 5.6 [2–20.4] 4.5 [2–20.6] 6.4 [3.7–7.2] 0.34 0.97 0.90–1.03
CRP (mg/L) 143[65–237] 143[45–248] 143[81–187] 0.81 1.00 0.99–1.01
Differences between groups were obtained using univariate logistic regression analysis. Abbreviations: SAP, systolic arterial pressure; MAP, mean arterial
pressure; CVP, central venous pressure; RR, respiratory rate; PEEP, positive end expiratory pressure; ScvO2, central venous oxygen saturation; WBC,
white blood cells; Plt, platelets; AT, antithrombin; PCT, procalcitonin; CRP, C-reactive protein.
doi:10.1371/journal.pone.0172039.t001
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In this prospective, observational, cohort, multicenter study, a significant improvement in
organ function as assessed by trends of SOFA score over time has been observed for patients
with septic shock and AKI during treatment with HCO-CVVHD. The reduction in SOFA
score was observed early during the treatment, persisting up to 48 hrs after discontinuation of
HCO-CVVHD. Lactatemia and a higher KDIGO stage of AKI were independently associated
to short-term mortality.
The effects of HCO membranes in septic patients with AKI have been tested previously,
with conflicting results [17]. The lack of a standardized definition of HCO membranes (e.g.
high permeability, super high-flux) and the different settings and/or treatment modalities may
explain these non-homogeneous clinical results [7].
For standardization purpose, “high cut-off membranes” are nowadays defined as mem-
branes with a cut-off value that approximates the molecular weight of albumin (i.e. 60 KDa)
after blood exposure [12,13,18]. This feature is important to achieve clinically relevant clear-
ance of “filterable” toxins, such as inflammatory mediators [7,19–21].
Several small experimental and clinical studies have shown that the application of extracor-
poreal therapies with HCO filters in septic patients with AKI may improve organ function.
The pilot study by Morgera et al. showed significant reductions in APACHE II and Multiple
Organ Dysfunction Score (MODS) in patients filtered with HCO membranes versus standard
high-flux membranes [22]. In a retrospective study, we have previously shown a reduced need
of vasoactive drugs/mechanical ventilation and better short term survival during HCO-CVVHD
in patients with septic AKI sustained by gram-negative bacteria [23]. Furthermore, in a random-
ized controlled trial involving 30 septic patients with AKI, it was demonstrated that HCO-hemo-
filtration significantly reduced 48 hrs-SAPS II with respect to baseline [24]. Nevertheless, no
definitive evidence of reduced long-term mortality has been established for HCO-CVVHD
[6,7,23].
In our study, variations in SOFA score and reduced need for vasopressors were the hall-
marks of efficacy of treatments in terms of organ dysfunction improvement. Indeed, we
Table 2. HCO-CVVHD treatment parameters across the groups.
Tot Survivors (N = 30) Non-Survivors (N = 8) p OR 95%CI
Weight (Kg) 71 [67; 78] 71 [66; 78] 72 [70; 77.5] 0.53 1.05 0.91–1.21
Precribed dose (ml/kg/hr) 35 35 35
Qb (ml/min) 132.5 [125;143] 132.5 [125; 140] 132 [124; 147.5] 0.72 1.01 0.93–1.10
Qd (ml/hr) 2350 [2214; 2587] 2280 [2094; 2511] 2388 [2228; 2448] 0.76 1.00 0.99–1.00
NET UF (ml/hr) 73.5 [61; 86] 73.5 [62; 87] 74 [56.5; 86] 0.74 0.99 0.94–1.04
Downtime (min) 86.6 [38; 124.9] 80 [24.9; 125.5] 91.8 [60.9; 121.8] 0.63 1.00 0.99–1.01
Delivered dose (ml/kg/hr) 32.89 [31.96; 34.07] 33.05 [31.95; 34.39] 32.77 [32.04; 33.52] 0.62 0.86 0.47–1.57
Delivered/Prescribed dose (%) 93.9 [91.3; 97.4] 94.4 [91.3; 98.3] 93.6 [91.5; 95.8] 0.63 0.95 0.77–1.17
Anticoagulation 0.63 1.00 0.98–1.01
Heparin 17 (44.7%) 13 (43.3%) 4 (50%)
No-Anticoagulation 21 (55.3%) 17 (56.7%) 4 (50%)
CRRT requirements after 72 hrs 12 (40%) 12 (40%) -
No-CRRT 18 (60%) 18 (60%)
HCO-CVVHD 2 (6.7%) 2 (6.7%)
HF-CVVHDF 10 (33.3%) 10 (33.3%)
Patients have been treated without anticoagulation to reduce risk of bleeding after surgical source control. Differences between groups were obtained using
univariate logistic regression analysis. Abbreviations: Qb, Blood flow; Qd, Dialysate flow; NET UF, Net ultrafiltration, HF-CVVHDF, Hemodiafiltration with
high-flux membrane.
doi:10.1371/journal.pone.0172039.t002
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observed a significant SOFA score reduction (greater than 2.5 points) already at 48 hrs of
HCO-CVVHD treatment (see Fig 2). Although the observational nature of this study does not
allow to univocally advocate this effect to HCO-CVVHD, some considerations can be done.
The observed reductions in SOFA score was greater than the mean reduction reported for
similar septic patients not treated with HCO-CVVHD [10]. A more pronounced and earlier
reduction in SOFA score has been observed among Survivors than non-Survivors patients (Fig
2). Of note, SOFA score lowered as earlier as in 6 hours in treated survivors, reaching signifi-
cance in 12 hours: making it an early predictor of survival during HCO-CVHHD (see Fig 2).
This observed reduction was more pronounced and earlier even to that described in literature
for septic patients with AKI and a favorable ICU outcome not treated with HCO-CVVHD
[10]. This may suggest a possible positive effect of HCO-CVVHD in our population.
Consistently, the improvement of SOFA score was associated with improved hemodynam-
ics and a significant reduction in vasoactive need, in particular norepinephrine [23,25] (see
Table 3). In Survivors, a significant reduction of norepinephrine dose was already evident 6
hours after HCO-CVVHD initiation. In several studies, hemodynamic stability has been corre-
lated with the reduction of inflammatory mediators obtained with HCO [26]. In particular, an
effective transmembrane removal of inflammatory mediators by means HCO, has been dem-
onstrated for IL-6 and TNF-a [27–29]. Similarly, also in this cohort of septic patients, median
values of TNF-a and IL-6 significantly lowered during HCO-CVVHD (p<0.05, see Table 3).
Fig 2. SOFA score. Mean and SD of SOFA scores cumulatively observed for the entire population at the
baseline, and then at 6, 12, 24 and 48 hrs after HCO-CVVHD initiation; and at 24 and 48 hrs after
HCO-CVVHD discontinuation (Panel A). In Panel B, SOFA scores are shown for each subgroup (Survivors
and non-Survivors). * Value statistically different to the baseline through statistical test for pairs data. † Value
statistically different between groups through statistical test for unpaired data.
doi:10.1371/journal.pone.0172039.g002
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Table 3. Clinical and biochemical parameters for both the overall population and the Survivors and non-Survivors subgroups.
Variables t0 (baseline) t6 t12 t24 t48 t post-24 t post-48
Sample size (pts) 38 38 38 37 34 30 30
Survivors 30 30 30 30 30 30 30
Non-Survivors 8 8 8 7 4 - -
Norepinephrine (mcg/kg/
min)
0.20 [0.15–0.30] 0.20 [0.10–
0.30]
0.20 [0.05–
0.25]*
0.10 [0–0.23]* 0.10 [0–0.20]* 0.05 [0–0.10]* 0 [0–0.10]*
Survivors 0.23 [0.15–0.30] 0.18 [0.10–
0.30]*
0.18 [0–0.25]* 0.08 [0–0.15]*† 0.06 [0–0.10]*† 0.05 [0–0.10]* 0 [0–0.10]*
Non-Survivors 0.18 [0.08–0.33] 0.20 [0.13–
0.25]
0.20 [0.09–
0.25]
0.20 [0.20–
0.30]†
0.20 [0.20–
0.25]†
- -
SAP (mmHg) 103±27 106±20 110±24 106±26 117±27* 123±23* 121±22*
Survivors 105±26 110±18† 115±23† 112±17† 121±24*† 123±23* 121±22*
Non-Survivors 95±27 91±20† 92±17 79±36† 83±28† - -
PAM (mmHg) 65±15 68±13 69±12 69±14 72±16* 71±18 73±13
Survivors 67±15 71±12*† 71±12*† 71±13 75±14*† 70±18# 72±13
Non-Survivors 60±14 56±13† 59±10† 62±18 50±17† - -
HR (bpm) 83 [80–100] 87 [80–95] 83 [76–97] 80 [75–90]* 79 [70–88]* 80 [70–90]* 80 [70–90]*
Survivors 83 [80–99] 88 [78–95] 80 [76–95] 80 [74–85]* 77 [70–85]* 80 [70–90]* 80 [70–90]*
Non-Survivors 88 [80–106] 82 [80–102] 94 [80–106] 91 [75–107] 90 [75–90] - -
CVP (mmHg) 12±4 13±3 12±4 13±4 12±4 11±4 11±4
Survivors 11±4 12±3 11±4 12±4 12±4 11±3 11±3
Non-Survivors 13±5 14±2 12±3 14±4 13±3 - -
RR (breath/min) 18±6 17±5 16±5 16±5 17±5 18±5 18±5
Survivors 18±6 17±5 15±5* 16±5 17±6 18±5 18±5
Non-Survivors 18±5 18±4 18±3 19±5 17±3 - -
PaO2/FiO2 230±126 246±101 243±101 266±106 268±128 308±109* 297±110*
Survivors 227±117 247±92 247±96 276±101* 276±130* 308±109* 297±110*
Non-Survivors 241±166 242±137 229±123 222±120 209±115* - -
Urinary output (ml/h) 40 [0–80] 15 [0–50]* 18 [0–60] 10 [0–50] 20 [0–50] 83 [10–100]* 100 [20–150]*
Survivors 50 [0–80] 20 [0–50] † 40 [10–60] † 20 [0–50] 20 [0–50] † 83 [10–100]* 100 [20–150]*
Non-Survivors 10 [0–70] 0 [0–0] † 0 [0–10] † 0 [0–20] 0 [0–0] † - -
Serum creatinine (mg/dl) 1.8 [1.3–2.6] 1.5 [1.1–1.9]* 1.3 [0.9–1.5]* 1.1 [0.8–1.5]* 0.8 [0.6–1.2]* 1.2 [0.7–1.6]* 1.2 [0.7–1.9]*
Survivors 1.9 [1.4–2.8] 1.7 [1.1–2]* † 1.3 [1–1.8]* † 1.1 [0.8–1.6]* 0.8 [0.7–1.3]* 1.2 [0.7–1.6]* 1.2 [0.7–1.9]*
Non-Survivors 1.4 [1.3–1.5] 1.1 [1–1.4] † 1 [0.8–1.3]* † 0.9 [0.8–1.3]* 0.7 [0.4–1.1] - -
Urea (mg/dl) 0.8 [0.6–1.4] 0.7 [0.5–1.1]* 0.6 [0.4–0.9]* 0.5 [0.4–0.8]* 0.3 [0.3–0.5]* 0.6 [0.4–0.8]* 0.7 [0.3–1.1]*
Survivors 0.9 [0.6–1.7] 0.7 [0.4–1.2]* 0.7 [0.4–0.9]* 0.5 [0.4–0.8]* 0.4 [0.3–0.7]* 0.6 [0.4–0.8]* 0.7 [0.3–1.1]*
Non-Survivors 0.7 [0.4–0.8] 0.6 [0.5–0.8] 0.5 [0.3–0.7] 0.4 [0.3–0.6] 0.3 [0.2–0.4] - -
Lactate (mmol/L) 2.5 [1.5–4.8] 2.2 [1.7–5.1] 2 [1.3–3.4]* 1.9 [1.2–3]* 1.7 [1–2.4]* 1.3 [0.8–1.7]* 1 [0.7–1.6]*
Survivors 2.4 [1.4–3.3] † 1.9 [1.7–4.1] † 1.7 [1.2–2.8]* † 1.6 [1–2.1]* † 1.7 [1–2]* † 1.3 [0.8–1.7]* 1 [0.7–1.6]*
Non-Survivors 6.3 [3.7–14.3] † 6 [3.2–14.2] † 6.5 [2.3–14.7] † 3 [2.6–13.7] † 10.7 [2.9–15] † - -
ScvO2 (%) 58±14 65±12* 66±11* 67±11* 69±7* 72±6* 76±6*
Survivors 60±15 68±10*† 70±8*† 71±7*† 69±7* 72±6* 76±6*
Non-Survivors 53±14 52±11† 53±11† 51±11† 62±8* - -
WBC (109/L) 15.8 [8–27.2] 16.4 [10.2–
29.6]
14.7 [8.8–26.4] 13.9 [9.1–23.4] 13.3[7.8–22.4] 12.4 [7.5–16.8]* 13.2 [6.9–
16.6]*
Survivors 16.2 [8–27.2] 15.6 [10.2–
29.9]
14.6 [8.8–26.4] 14.5 [9.1–27.6] 13.7 [9.8–22.8] 12.4 [7.5–16.8]* 13.2 [6.9–
16.6]*
Non-Survivors 15 [9.8–26.7] 20.6 [11.6–
25.5]
17.6 [10.3–
26.2]
12 [3.8–22.8] 8.1 [2.7–15.2] - -
Plt (109/L) 96.5 [67–226] 105 [62–230] 102.5 [65–204] 105 [50–201] 83 [40–153]* 94.5 [59–153]* 109 [66–151]
(Continued )
Organ dysfunction during HCO-CVVHD
PLOS ONE | DOI:10.1371/journal.pone.0172039 February 16, 2017 8 / 13
We are aware that, because of the observational nature of this study, a causal correlation
between the reduction of inflammatory mediators and HCO-CVVHD cannot be univocally
defined. Interestingly, this effect was particularly evident for Survivors, paralleling the reduc-
tion in SOFA score and norepinephrine (Table 3). Indeed, considering that no differences
were observed between groups for IL-6 or TNF-a levels before the HCO-CVVHD initiation,
we cannot assume that baseline cytokine levels might be considered as outcome predictors in
our patients. Nevertheless, the statistically significant reduction exclusively observed among
survivors, might suggest that an early reduction of cytokine levels during the treatment might
be a potential predictor for positive outcome during HCO-CVVHD. Although clinical fasci-
nating, this cytokines reduction during extracorporeal treatments has not been univocally
related to positive outcome in septic patients; furthermore, considering the high costs and the
limited laboratory feasibility for cytokine analysis, the reduction in circulating cytokines might
unlikely be proposed as predictor in the ICU clinical routine practice.
Table 3. (Continued)
Variables t0 (baseline) t6 t12 t24 t48 t post-24 t post-48
Survivors 100 [68–226] 107.5 [73–230] 108.5 [66–204] 109.5 [56–201] 101.5 [40–
159]* †
94.5 [59–153]* 109 [66–151]
Non-Survivors 83 [33.5–206.5] 75.5 [26.5–195] 66 [21.5–192]* 105 [18–254] 28 [7–49] † - -
AT III (%) 60±21 51±19* 48±20* 50±18* 54±22 68±24 70±26
Survivors 62±21 54±18*† 52±19*† 53±18* 56±21 68±24 70±26
Non-Survivors 54±23 38±19*† 32±19*† 40±16 35±28 - -
Albumin (g/L) 24.4±2.3 23±2 23.7±2.2 24.9±1.8 25.1±2.3 26.6±1.7 26.8±1.5
Survivors 243±2.3 22.9±2.1 23.9±2.1 24.9±1.8 25.2±2.2 26.6±1.7 26.8±1.5
Non-Survivors 24.8±2.6 23.3±2.1 22.5±2.1 25±2.1 24.3±2.6 - -
PCT (ng/ml) 5.6 [2–20.4] 4.7 [1.5–16.3]* 2.9 [1.4–17.8]* 2.9 [1.1–16.9]* 1.3 [0.4–2.6]* 1.6 [0.4–4.3]* 1.3 [0.4–2.6]*
Survivors 4.5 [2–20.6] 3.4 [1.4–16.3]* 2.7 [1.2–17.8]* 2.2 [0.9–17.2]* 2.2 [0.8–12.1]* 1.6 [0.4–4.3]* 1.3 [0.4–2.6]*
Non-Survivors 6.4 [3.7–7.2] 5.7 [4.3–13.6] 4 [2.4–14.3] 4.4 [1.7–14.4] 1.3 [1.1–4.3] - -
PCR (mg/L) 143 [65–237] 135 [50–231] 135 [45–229] 102 [52–217] 96 [49–166]* 55 [27–85]* 44 [20–89]*
Survivors 143 [45–248] 121 [42–237] 118 [40–236] 101 [34–237] 90 [31–157]* 55 [27–85]* 44 [20–89]*
Non-Survivors 143 [81–187] 152 [75–216] 152 [84–214 169 [62–217] 149 [100–193] - -
TNFα (pg/ml) 46.1 [21.2–113] 38.3 [11.4–
52.8]*
32.5 [15.4–
46.4]*
23.5 [15.2–35]*
Survivors 76.6 [22.9–167] 39.9 [13.9–
58.2]*
33.8 [20.9–
49.7]*
23.5 [15.2–35]*
Non-Survivors 24 [17.4–94 14.7 [10.5–
48.8]*
15.4[10.4–
32.5]*
-
IL-6 (pg/ml) 228 [98.3–1091] 85.4 [61–171]* 99.1 [40–178]* 54.4 [29.7–
141.4]*
Survivors 233 [167–1450] 108.2 [69.3–
406]*
108.1[68.8–
193]*
54.4 [29.7–
141.4]*
Non-Survivors 98.3 [59.8–
1091]
39.7 [38.3–165] 32.7[17–165] -
IL-10 (pg/ml) 28.1 [10.8–87.4] 20.1 [7.5–29.7] 12.2 [8.1–21] 10 [5.2–30.3]
Survivors 39.5 [10.5–
198.2]
21 [5.5–60.9] 11.8 [9.65–
33.3]
10 [5.2–30.3]
Non-Survivors 11.7 [11.5–28.1] 14.6 [10.7–
20.1]
20.9[7.9–21] -
* Value statistically different to the baseline using statistical test for pairs data.
† Value statistically different between groups using statistical test for unpaired data.
doi:10.1371/journal.pone.0172039.t003
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The observed ICU-mortality was lower to that expected from literature and based to base-
line APACHE II score. In particular, with a baseline APACHE II score of 37.55±3.55 (37.6
±3.06 and 38±2.92 for Survivors and non-Survivors, respectively), a 71% mortality rate could
be expected in this population. Interestingly, overall, we observed an in-hospital mortality rate
Fig 3. Circulating levels of inflammatory mediators. Concentrations of mediators are expressed in a
logarithmic scale.
doi:10.1371/journal.pone.0172039.g003
Organ dysfunction during HCO-CVVHD
PLOS ONE | DOI:10.1371/journal.pone.0172039 February 16, 2017 10 / 13
of 39.5%. The identification of specific baseline patients’ characteristics associated with early
(72 hrs) ICU-mortality during HCO-CVVHD may be of prognostic values for physicians
using this invasive extracorporeal treatment. The initial KDIGO-AKI stage and serum lactate
levels were independently associated with survival at 72 hour of HCO-CVVHD. The baseline
values of serum lactate concentration were different between the groups: 2.4 vs 6.3 mEq/l in
Survivors and non-Survivors, respectively. In light of this, it would be expected that serum lac-
tates concentration (particularly values higher than 5.2 mmol/l) and AKI stage correlate with
mortality. It can be thus speculated that early initiation of extracorporeal treatment, at lower
degrees of global hypoxia and organ dysfunction, may positively affect the outcome [30–33].
In light of this, even though the observational nature of the study does not allow to correlate
clinical improvements with HCO-CVVHD, our results suggest that HCO-CVVHD may retain
a positive clinical effect in patients with septic AKI. Clearly, results on these outcomes cannot
be generalized for all septic patients. Indeed, although the mean SOFA score observed by Car-
bonell et al.[10] (used for sample size calculation) is consistent with those observed in other
important studies on similar population as ALBIOS [34], EUPHAS [35]or even in the most
recent ABDOMIX [36], a wide dispersion of SOFA score values has been observed, also within
each single study. As a consequence, SOFA score utilized for sample size evaluation might not
necessarily align that observed in our septic shock population, and thus potentially under-
powering this study.
Conclusions
HCO-CVVHD was associated with a significant reduction in SOFA score in a cohort of
patients with septic shock and AKI. This effect was evident early during the treatment and
associated with a significant reduction of circulating inflammatory mediators, such as IL-6 and
TNF-a. Serum lactate levels and the initial stage of AKI were statistically associated to 72 hrs-
ICU mortality.
Supporting information
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(PDF)
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